Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) using a proprietary cell-free platform. The STRO news page on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures so readers can follow how Sutro’s ADC pipeline and corporate strategy evolve over time.
News about Sutro frequently covers pipeline milestones, such as the initiation of a Phase 1 trial for STRO-004, a tissue factor–targeting exatecan ADC in TF-expressing solid tumors, and preclinical progress for programs like STRO-006 and the dual-payload candidate STRO-227. The company also issues updates on collaborations, including its work with Astellas on dual-payload immunostimulatory ADCs, and presentations at major scientific meetings like the World ADC Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Investors and observers will find corporate and financial communications here as well, including quarterly financial results, details of organizational restructuring aimed at extending the company’s cash runway, and information about actions related to its Nasdaq listing status, such as the 1-for-10 reverse stock split and subsequent confirmation of regained compliance with the minimum bid price requirement.
In addition, Sutro regularly announces participation in healthcare and investor conferences, virtual R&D days, and other events where management discusses the ADC platform, single- and dual-payload programs, and near- and long-term priorities. Bookmark this page to access a consolidated view of Sutro Biopharma’s latest press releases, scientific highlights, and market-facing updates related to its oncology-focused ADC pipeline.
Sutro Biopharma (STRO) reported a strong performance for 2021, with revenue increasing to $61.9 million from $42.7 million in 2020, driven by collaborations with Merck, BMS, and EMD Serono. The company is advancing its lead candidate, STRO-002, which targets ovarian cancer, completing its Phase 1 trial enrollment and planning a registrational path forward. However, operating expenses rose to $160.4 million, up from $113.8 million, partly due to stock-based compensation. Sutro's cash reserves stood at $229.5 million, providing runway into late 2023.
Sutro Biopharma (NASDAQ: STRO), a clinical-stage company based in South San Francisco, announced that CEO Bill Newell will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 11:15 a.m. ET. The live presentation will be available via webcast on the company's website. Sutro focuses on advanced oncology therapeutics, using its XpressCF® platform to develop candidates like STRO-001 and STRO-002, currently in clinical trials for B-cell malignancies and ovarian cancer, respectively.
Sutro Biopharma (NASDAQ: STRO) announced interim results from its Phase 1 study of STRO-002, a folate receptor alpha-targeting ADC for advanced ovarian cancer. The study, involving 44 patients with extensive prior treatments, reported an overall response rate (ORR) of 33%. Notably, patients starting at a 5.2 mg/kg dose level exhibited a 47% ORR. Encouraging safety signals included no new complications. Sutro plans to advance STRO-002 into further clinical phases, leveraging its Fast Track designation.
Sutro Biopharma (NASDAQ: STRO) has entered an exclusive license agreement with Tasly Biopharmaceuticals for the development and commercialization of STRO-002 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Sutro will receive an upfront payment of $40 million and could earn up to $345 million in milestone payments. STRO-002 is currently in clinical trials for ovarian and endometrial cancers. Sutro retains rights outside of Greater China and will receive royalties based on STRO-002's net sales.
Sutro Biopharma (STRO) announced a KOL virtual event on Jan. 5, 2022, to share interim data from the Phase 1 study of STRO-002, an antibody-drug conjugate for advanced ovarian cancer. The trial, which enrolled 44 patients by Nov. 2021, aims to assess the efficacy, safety, and tolerability of STRO-002 in patients who have undergone multiple prior therapies. The event will feature presentations from Sutro management and Dr. R. Wendel Naumann from the Levine Cancer Institute.
Sutro Biopharma (NASDAQ: STRO) announced new nonclinical data for STRO-002 and STRO-001 presented at the ASH 2021 conference, showcasing potential therapies for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Research led by Fred Hutchinson Cancer Research Center identifies FOLR1 and CD74 as actionable targets. STRO-002 exhibited strong efficacy against high-risk AML subtypes, while STRO-001 demonstrated significant cytotoxicity in both AML and ALL cells. The data supports ongoing clinical trials for both products in treating various cancer indications.
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in two virtual investor conferences. The Piper Sandler 33rd Annual Healthcare Conference is scheduled for November 22, 2021, at 10:00 a.m. ET, featuring a pre-recorded fireside chat. The 4th Annual Evercore ISI HealthCONx Conference will take place on November 30, 2021, at 10:05 a.m. ET, with a live fireside chat. Webcasts are accessible via Sutro's Investor Relations page, with archived replays available for 30 days.
Sutro Biopharma (NASDAQ: STRO) announced the appointment of Heidi Hunter to its Board of Directors, effective November 17, 2021. Hunter brings over 25 years of biotech leadership experience, having held significant roles at Cardinal Health, UCB, Boehringer Ingelheim, and IQVIA. CEO Bill Newell highlighted her expertise in driving the development and commercialization of new medicines. Sutro focuses on advancing innovative cancer and autoimmune therapeutics, including its leading candidates STRO-001 and STRO-002, currently in Phase 1 trials.
Sutro Biopharma (NASDAQ: STRO) reported financial results for Q3 2021, highlighting a revenue drop to $8.5 million from $17.8 million in Q3 2020. Operating expenses surged to $43.2 million, reflecting increased R&D and G&A costs. Key developments include completed enrollment for the STRO-002 Phase 1 dose-expansion cohort targeting advanced ovarian cancer and ongoing dose escalation for STRO-001 in B-cell malignancies. Sutro has a cash runway into H2 2023, with substantial cash reserves of $254.2 million as of September 30, 2021.
Sutro Biopharma (NASDAQ: STRO), a clinical-stage drug development company, announced CEO Bill Newell will present at three virtual investor conferences in November 2021. The presentations include:
- Credit Suisse 30th Annual Healthcare Conference: Nov. 10, 2021, 4:20 p.m. EST
- Stifel Virtual Healthcare Conference: Nov. 15, 2021, 1:20 p.m. EST
- Jefferies London Healthcare Conference: Nov. 18, 2021, 3:00 a.m. EST
Live webcasts can be accessed via the company's website.